anti-IL-33 (mouse) mAb (rec.) (blocking) (Bondy-1-1)

AdipoGen Life Sciences
Product Code: AG-27B-0013
Product Group: Primary Antibodies
CodeSizePrice
AG-27B-0013-C100100 ug£370.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Antibody Clonality: Recombinant Antibody
Regulatory Status: RUO
Target Species: Mouse
Applications:
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Functional Study
Shipping:
-20°C
Storage:
-20°C

Images

1 / 1
Binding of IL-33 (mouse) to ST2 /IL-1RAcp is inhibited by IL-33 (mouse), mAb (rec.) (blocking) (Bondy-1-1) (AG-27B-0013). Methods: IL-33 (mouse) was coated on an ELISA plate at 1?g/ml. IL-33 (mouse), mAb (rec.) (blocking) (Bondy-1-1) (AG-2

Binding of IL-33 (mouse) to ST2 /IL-1RAcp is inhibited by IL-33 (mouse), mAb (rec.) (blocking) (Bondy-1-1) (AG-27B-0013). Methods: IL-33 (mouse) was coated on an ELISA plate at 1?g/ml. IL-33 (mouse), mAb (rec.) (blocking) (Bondy-1-1) (AG-2

Further Information

Alternate Names/Synonyms:
Interleukin-33; IL-1F11; NF-HEV
Concentration:
1mg/ml
EClass:
32160000
Endotoxin:
<0.01EU/µg purified protein (LAL test; Lonza).
Form (Short):
liquid
Formulation:
Liquid. In PBS containing 10% glycerol and 0.02% sodium azide.
Handling Advice:
After opening, prepare aliquots and store at -20°C.Avoid freeze/thaw cycles.
Immunogen:
Mouse recombinant IL-33.
Long Description:
Recombinant Antibody. Recognizes mouse IL-33. Species cross-reactivity: Mouse. Clone: Bondy-1-1. Isotype: Mouse IgG2b. Applications: ELISA, FUNC (Blocking). Host: Purified from HEK 293 cell culture supernatant. Liquid. In PBS containing 10% glycerol and 0.02% sodium azide. Interleukin-33 (IL-33; HF-NEV; IL-1F11), a member of the IL-1 family of cytokines, is expressed by many cell types following pro-inflammatory stimulation and is thought to be released upon cell lysis. IL-33 binds to and signals through ST2 (IL-1R1) and its stimulation recruits MYD88, IRAK, IRAK4 and TRAF6, followed by phosphorylation of ERK1 (MAPK3)/ERK2 (MAPK1), p38 (MAPK14) and JNK. The ability of IL-33 to target numerous immune cell types, like Th2-like cells, mast cells and B1 cells, and to induce cytokine and chemokine production underlines its potential in influencing the outcome of a wide range of diseases, such as arthritis, asthma, atopic allergy & anaphylaxis, cardiovascular disease/atherosclerosis, nervous system diseases and sepsis. Anti-IL-33, mAb (recombinant) (blocking) (Bondy-1-1) is an antibody developed by antibody phage display technology using a human naive antibody gene library. These libraries consist of scFv (single chain fragment variable) composed of VH (variable domain of the human immunoglobulin heavy chain) and VL (variable domain of the human immunoglobulin light chain) connected by a polypeptide linker. The antibody fragments are displayed on the surface of filamentous bacteriophage (M13). This scFv was selected by affinity selection on antigen in a process termed panning. Multiple rounds of panning are performed to enrich for antigen-specific scFv-phage. Monoclonal antibodies are subsequently identified by screening after each round of selection. The selected monoclonal scFv is cloned into an appropriate vector containing a Fc portion of interest and then produced in mammalian cells to generate an IgG like scFv-Fc fusion protein.
NCBI, Uniprot Number:
Q8BVZ5
Other data:
anti-IL-33 (mouse), monoclonal antibody (recombinant) (Bondy-1-1) is composed of human variable regions (VH and VL) (lambda-chain) of immunoglobulin fused to the mouse lgG2b Fc domain.
Package Type:
Plastic Vial
Product Description:
Interleukin-33 (IL-33; HF-NEV; IL-1F11), a member of the IL-1 family of cytokines, is expressed by many cell types following pro-inflammatory stimulation and is thought to be released upon cell lysis. IL-33 binds to and signals through ST2 (IL-1R1) and its stimulation recruits MYD88, IRAK, IRAK4 and TRAF6, followed by phosphorylation of ERK1 (MAPK3)/ERK2 (MAPK1), p38 (MAPK14) and JNK. The ability of IL-33 to target numerous immune cell types, like Th2-like cells, mast cells and B1 cells, and to induce cytokine and chemokine production underlines its potential in influencing the outcome of a wide range of diseases, such as arthritis, asthma, atopic allergy & anaphylaxis, cardiovascular disease/atherosclerosis, nervous system diseases and sepsis. Anti-IL-33, mAb (recombinant) (blocking) (Bondy-1-1) is an antibody developed by antibody phage display technology using a human naive antibody gene library. These libraries consist of scFv (single chain fragment variable) composed of VH (variable domain of the human immunoglobulin heavy chain) and VL (variable domain of the human immunoglobulin light chain) connected by a polypeptide linker. The antibody fragments are displayed on the surface of filamentous bacteriophage (M13). This scFv was selected by affinity selection on antigen in a process termed panning. Multiple rounds of panning are performed to enrich for antigen-specific scFv-phage. Monoclonal antibodies are subsequently identified by screening after each round of selection. The selected monoclonal scFv is cloned into an appropriate vector containing a Fc portion of interest and then produced in mammalian cells to generate an IgG like scFv-Fc fusion protein.
Purity:
>95% (SDS-PAGE)
Source / Host:
Produced without the use of animals. Purified from HEK 293 cell culture supernatant.
Specificity:
Recognizes mouse IL-33.
Transportation:
Non-hazardous
UNSPSC Category:
Primary Antibodies
UNSPSC Number:
12352203
Use & Stability:
Stable for at least 1 year after receipt when stored at -20°C.

References

Regulation of de novo adipocyte differentiation through crosstalk between adipocytes and pre-adipocytes: T.D. Challa, et al.; Diabetes 64, 4075 (2015) | Male-specific IL-33 expression regulates sex-dimorphic EAE susceptibility: A.E. Russi, et al.; PNAS 115, E1520 (2018)